CODE OF PRACTICE FOR ASSISTED REPRODUCTIVE TECHNOLOGY UNITS

INTERNATIONAL EDITION

Fertility Society of Australia

Reproductive Technology Accreditation Committee

(October 2018)
© Fertility Society of Australia 2018

ISBN: 978-0-646-91934-8

Copyright statement
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Fertility Society of Australia.

This document is adapted from the RTAC Code of Practice for Assisted Reproductive Technology Units October 2017 for application to Assisted Reproductive Technology clinics outside Australia and New Zealand.

For more information, contact:
Fertility Society of Australia
c/- Waldron Smith Management
119 Buckhurst Street
South Melbourne, Victoria 3205
Telephone: +61 3 9645 6359
Website: http://www.fertilitysociety.com.au
# CONTENTS

## INTRODUCTION

The RTAC Code of Practice ................................................................................. 4

The RTAC Code of Practice Technical Bulletins ............................................. 6

### PART 1 CRITICAL CRITERIA

<table>
<thead>
<tr>
<th>CRITICAL CRITERIA</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC 1. Compliance</td>
<td>8</td>
</tr>
<tr>
<td>CC 2. Key Personnel</td>
<td>8</td>
</tr>
<tr>
<td>CC 2.1. Medical Director</td>
<td>8</td>
</tr>
<tr>
<td>CC 2.2. Scientific Director</td>
<td>8</td>
</tr>
<tr>
<td>CC 2.3. Nurse Manager</td>
<td>9</td>
</tr>
<tr>
<td>CC 2.4. Senior Counsellor</td>
<td>9</td>
</tr>
<tr>
<td>CC 3. Disaster Management</td>
<td>10</td>
</tr>
<tr>
<td>CC 4. Validation Consent</td>
<td>10</td>
</tr>
<tr>
<td>CC 5. Management of Infection Risk</td>
<td>11</td>
</tr>
<tr>
<td>CC 6. Identification and Traceability</td>
<td>11</td>
</tr>
<tr>
<td>CC 7. Donor and Surrogacy Requirements</td>
<td>11</td>
</tr>
<tr>
<td>CC 8. Cryostorage of Gametes and Embryos</td>
<td>12</td>
</tr>
<tr>
<td>CC 9. Adverse Events</td>
<td>12</td>
</tr>
<tr>
<td>CC 10. Multiple Pregnancy</td>
<td>12</td>
</tr>
<tr>
<td>CC 11. Data Monitoring</td>
<td>13</td>
</tr>
<tr>
<td>CC 12. Data Reporting</td>
<td>13</td>
</tr>
</tbody>
</table>

### PART 2 GOOD PRACTICE CRITERIA

<table>
<thead>
<tr>
<th>GOOD PRACTICE CRITERIA</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPC 1. Quality Management System (QMS)</td>
<td>15</td>
</tr>
<tr>
<td>GPC 2. Stakeholder Feedback</td>
<td>17</td>
</tr>
<tr>
<td>GPC 3. Medical Management</td>
<td>17</td>
</tr>
<tr>
<td>GPC 4. Information</td>
<td>18</td>
</tr>
<tr>
<td>GPC 4.1. Patient Information</td>
<td>18</td>
</tr>
<tr>
<td>GPC 4.2. Public Information</td>
<td>18</td>
</tr>
<tr>
<td>GPC 5. Medication Management</td>
<td>19</td>
</tr>
<tr>
<td>GPC 6. Emergency Care</td>
<td>20</td>
</tr>
<tr>
<td>GPC 7. Ovarian Hyperstimulation Syndrome</td>
<td>20</td>
</tr>
</tbody>
</table>

### PART 3 ESTABLISHMENT AND CLOSURE OF AN ART UNIT

<table>
<thead>
<tr>
<th>ESTABLISHMENT AND CLOSURE OF AN ART UNIT</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Certification of an ART Unit</td>
<td>22</td>
</tr>
<tr>
<td>Closure or Discontinuation of Certification of an ART Unit</td>
<td>22</td>
</tr>
</tbody>
</table>

### ATTACHMENT 1

<table>
<thead>
<tr>
<th>ATTACHMENT 1</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor &amp; Surrogacy Requirements</td>
<td>23</td>
</tr>
</tbody>
</table>

### ATTACHMENT 2

<table>
<thead>
<tr>
<th>ATTACHMENT 2</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions</td>
<td>25</td>
</tr>
</tbody>
</table>

### ATTACHMENT 3

<table>
<thead>
<tr>
<th>ATTACHMENT 3</th>
<th>PAGE</th>
</tr>
</thead>
</table>

---

Issued: 2014
Review: September 2018
Issue no: 2
RTAC COP International Edition 2018

Page 3 of 28
Approved by: FSA Board of Directors
INTRODUCTION

The RTAC Code of Practice

This Code of Practice for Assisted Reproductive Technology (ART) Units has been developed by the Reproductive Technology Accreditation Committee (RTAC) of the Fertility Society of Australia (FSA). The purpose of the RTAC Code of Practice is to:

- Promote continuous improvement in the quality of care offered to people accessing fertility treatment.
- Provide a framework and set criteria for the auditing process that leads to certification of Units that deliver fertility services.
- Ensure the auditing process is carried out in an independent, non-adversarial and constructive manner.

Fundamental to the delivery of ART services is that patients and their offspring remain the most important consideration in all decisions. Units aspire to deliver services in a manner that recognises patients' cultural and individual values and beliefs, upholds patients' dignity and privacy, and supports the rights of offspring born through ART to know their genetic origins and to have optimal health outcomes.

Background:

The code was first introduced in 1986, when the FSA produced a series of standards as a guide for ART units. In 1987, RTAC was established and added explanatory notes to many of the original standards drawn up by the FSA. This initial code was revised in 1992, 1997, 2001 and 2005. It was fully rewritten in 2008 with revisions in 2010, 2014 and 2017.

The International Edition of the code was introduced in 2014 to facilitate its application in countries outside the jurisdiction of the regulatory laws of Australia and New Zealand. In addition to sections on establishing, renaming or closing an ART Unit, the International Code of Practice has two sets of criteria as defined in the Scheme rules, namely:

a) Critical criteria. These are audited annually at the surveillance audits, or in accordance with national legislation/regulations.

b) Good Practice criteria. These are audited at the initial certification audit and subsequently over a three year period of annual inspections, in accordance with the RTAC certification scheme. Where, in accordance with national legislation/regulations, assessments are less frequent than annually then all good practice criteria should be audited at each assessment.
<table>
<thead>
<tr>
<th>Criteria</th>
<th>Critical</th>
<th>Good Practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC 1. Compliance</td>
<td>GPC 1. Quality management system (QMS)</td>
<td></td>
</tr>
<tr>
<td>CC 2. Key personnel</td>
<td>GPC 2. Stakeholder feedback</td>
<td></td>
</tr>
<tr>
<td>CC 3. Disaster management</td>
<td>GPC 3. Medical management</td>
<td></td>
</tr>
<tr>
<td>CC 4. Valid consent</td>
<td>GPC 4. Information</td>
<td></td>
</tr>
<tr>
<td>CC 5. Management of infection risk</td>
<td>GPC 5. Medication management</td>
<td></td>
</tr>
<tr>
<td>CC 6. Identification and traceability</td>
<td>GPC 6. Emergency care</td>
<td></td>
</tr>
<tr>
<td>CC 7. Donor and surrogacy requirements</td>
<td>GPC 7. Ovarian hyperstimulation syndrome</td>
<td></td>
</tr>
<tr>
<td>CC 8. Cryostorage of gametes and embryos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC 9. Adverse events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC 10. Multiple pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC 11. Data monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC 12. Data reporting</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
RTAC Certification:

An ART Unit’s compliance with the RTAC International Code of Practice must be reviewed on a regular basis. An ART Unit includes associations, agencies, groups, independent practitioners and individuals accountable for the delivery of services to the patient.

The review is conducted as an audit by an independent Certification Body (CB) that is approved by the Joint Accreditation System of Australia and New Zealand (JAS-ANZ) or the Fertility Society of Australia.

Assisted Reproductive Technology (ART)

For the purposes of this Code of Practice, ART involves clinical treatments; counselling services; and laboratory procedures for the assessment and preparation of human oocytes, sperm or embryos. ART includes IVF; gamete intrafallopian transfer; zygote intrafallopian transfer; intracytoplasmic sperm injection; embryo or gamete cryopreservation; surgical sperm recovery; oocyte, semen or embryo donation; blastomere biopsy for preimplantation genetic diagnosis; gestational surrogacy and intrauterine insemination (IUI).

An ART Unit is a facility that uses, assesses and/or prepares human gametes and/or embryos for therapeutic service, possibly across a range of sites of clinical activity.

Scope of the Audit

The scope of the audit by a CB will include site visits to all ART units.

Application of the International Code of Practice

The International Code of Practice is to be observed in ART Units outside of Australia and New Zealand involved in the treatment of patients with assisted reproductive technology including donated gametes or embryos and IUI and desiring accreditation for compliance with the International Code of Practice.

Compliance:

ART units must also comply with relevant national legislation and regulations in the countries where they are located. Where there are conflicts between legislation, regulations and this Code of Practice, national legislation overrides regulations, guidelines and this Code of Practice.

Technical Bulletins:

From time to time RTAC will become aware of issues, questions or comments where it may consider assisting units to enhance the quality of their service to patients. A Technical Bulletin is an educational communication to all ART Units, and Bodies certifying units to the RTAC Code of Practice, offering advice and guidance. Technical Bulletins are not enforceable unless their content is incorporated into the Code of Practice. A current list of Technical Bulletins can be found at https://www.fertilitysociety.com.au/rtac/technical-bulletins.
PART 1  CRITICAL CRITERIA

(AUDITED ANNUALLY OR IN ACCORDANCE WITH NATIONAL LEGISLATION/REGULATIONS)
CC 1. Compliance

The ART Unit must comply with statutory and regulatory requirements.

It must provide evidence of:

a) Identification, communication of, and compliance with national statutory and regulatory requirements in regard to ART treatment including donation and surrogacy,

b) How changes to external requirements are integrated into work practices,

c) Communication, implementation, and review of all policies/procedures,

d) Compliance with the RTAC International Code of Practice, and

e) A record of the current signed Deed of Agreement with the FSA.

CC 2. Key personnel

The Unit must ensure access to competent staff, and these must include a Medical director, Scientific director, Nurse manager and Senior counsellor

The ART Unit must provide evidence of qualifications, training, education and experience of key personnel, and the requirements and responsibilities of these personnel are given below. In a Unit where any of these personnel do not normally work on site, the clinic must be able to demonstrate regular involvement of those personnel in clinical and quality control review of the clinic's activities.

CC2.1. Medical Director

The Medical Director is responsible for the clinical management within the Unit and the training, competency, and supervision of all clinicians involved in the Unit.

The Medical Director must be a specialist gynaecologist registered in the country of the clinic who has at least five years ART experience, and must demonstrate continuing medical education in the field of reproductive endocrinology and infertility.
CC2.2. Scientific Director

The Scientific Director is responsible for the scientific management within the Unit and the training, competency, and supervision of all scientists involved in the Unit.

The Scientific Director must have a minimum of four years of ART clinical laboratory experience, as well as experience in the management of a clinical embryology or clinical andrology laboratory as appropriate to services offered with demonstrable knowledge of and continuing education in all laboratory aspects of the Unit. In addition, the Scientific Director must have a higher degree (PhD, Masters or Postgraduate diploma) demonstrating a broadly-based scientific experience in reproductive biology, with expertise and/or specialised training in the physiology of reproduction, cell biology and biochemistry, statistics and problem solving.

CC2.3. Nurse Manager

The Nurse Manager is responsible for the nursing management within the Unit and the training, competency, and supervision of all nurses involved in the Unit.

The Nurse Manager must be a registered nurse or midwife in the country of the Unit with training in infertility nursing, must have three years of experience in the management of patients with infertility, and must demonstrate continuing nursing education in the field of infertility. In the absence of this period of experience there must be a well-documented orientation/training/supervision programme.

CC2.4. Senior Counsellor

The Senior Counsellor is responsible for the counselling management within the Unit and the training, competency, and supervision of all staff involved in counselling within the Unit to meet the requirements of attachment 1.

The Senior Counsellor must have tertiary qualifications in a clinical profession, recognised in the country of the unit, such as psychiatry, psychology, social work or counselling. In addition, the Senior Counsellor must be able to demonstrate current knowledge of infertility and infertility treatment, and be able to demonstrate continuing education in the field of infertility counselling.
CC 3. Disaster management

The Unit must minimise the risk of serious adverse outcomes following a disaster.

The ART Unit must:

a) Have contingency plans that address potential disaster and emergency scenarios including those specific to their location,

b) Ensure access to emergency equipment, power, and gas that is shown to work in critical areas such as surgical procedures and maintenance of embryo culture conditions,

c) Show evidence of working through scenarios,

d) Identify the principal components of the plans, and show them to be feasible and to work.

The ART Unit should have a policy, where possible, of open disclosure with patients adversely affected by disasters, emergencies and untoward events.

CC 4. Valid consent

The Unit must ensure that treatment only occurs with full valid consent.

The Unit must have a process to ensure that consent is obtained from all patients and/or donors (and, where relevant, their spouses or partners) before treatment commences. The Unit must provide patients with information that is accurate, timely and in formats appropriate to the patient. It must provide evidence of implementation and review of policies/procedures that:

a) Define the consenting process,

b) Ensure that consent is informed, voluntary, competent, specific, documented and remains current.

c) Define the extent and use of information should there be any requirement for data reporting and external audits, and

d) Ensure the availability of a process to allow informed consent in situations where there is difficulty of understanding.
CC 5. Management of infection risk

The Unit must manage the risk of infection transmission for all clinical and laboratory procedures undertaken within the ART Unit.

The ART Unit must have in place risk assessments, policies and procedures which ensure the minimisation of infection transmission risk:

a) Between donors of reproductive tissues and recipients or surrogates, between partners in sero-discordant couples, and between patients and donors, and

b) For staff handling biological material including infectious disease screening.

Where applicable, policies should define quarantine periods and tests to be performed.

CC 6. Identification and traceability

The ART Unit must ensure that gametes, embryos and patients are correctly identified and matched at all times.

The ART Unit must provide evidence of implementation and review of:

a) Policies and procedures to identify when, how and by whom the identification, matching, and verification are recorded for gametes, embryos and patients at all stages of the treatment process including digital and manual record keeping

b) The process that constitutes the traceability of gametes and embryos at all stages of the treatment cycle and associated digital and manual records including where transport is involved,

c) Regular (at least annual) audit of the patient, gamete and embryo identification process and associated digital and manual records.

d) A minimum of three forms of identification should be used to ensure traceability of all persons and specimens.

CC 7. Donor and surrogacy requirements

The ART Unit must ensure gametes, embryos and tissues are safe for donation and use in surrogacy arrangements and that appropriate counselling has been provided. Commercial surrogacy is not permitted.

The ART Unit must provide evidence of compliance with Attachment 1. It must supply to the Certifying Body audit team a list of all file codes involving donation divided according to sperm, oocytes and embryos, and surrogacy, in the previous calendar year. The Certifying Body audit team will select 3 (where available) from each category for full audit on the day.
CC 8. Cryostorage of gametes and embryos

The ART Unit must ensure the safe management of cryopreserved gametes, embryos and tissues. The ART Unit must provide evidence of implementation and review of policies/procedures:

- to identify, locate, retrieve and maintain cryopreserved material.
- to limit the time in storage, and ensure accordance with local guidelines and legislation where applicable.
- to manage the disposal of cryopreserved material.

CC 9. Adverse events

The ART Unit must acknowledge and investigate adverse events. The ART Unit must provide evidence of implementation and review of:

a) Policies/procedures to systematically collect, analyse causal factors, review and act on all adverse, unplanned and untoward events.

b) Adverse events, including serious adverse events and serious notifiable adverse events as defined in Attachment 3. Where required by local legislation or guidelines they should be reported to the relevant body and/or institution.

Notifiable Serious Adverse Events, as defined in Attachment 3, must be reported to RTAC through its secretariat and to the appropriate Certifying Body to facilitate audit of responses to the Adverse Event.

CC 10. Multiple pregnancy

The ART Unit must minimise the incidence of multiple pregnancy. The ART Unit must provide evidence of implementation and review of policies/procedures that:

a) Regularly audit (at least annually) multiple pregnancy rates and corrective actions that continuously attempt to reduce the incidence of multiple pregnancies in all treatment cycles, including artificial insemination even when the insemination is done offsite, The aim for multiple pregnancy rate should be less than 10%.

b) Recommend to patients that no more than one embryo or oocyte is transferred in the first treatment cycle where the oocyte is obtained from a woman aged less than 35 years at the time of oocyte collection.

c) Ensure that no more than two embryos or oocytes are transferred in any one treatment cycle in a woman under the age of 40 years at the time of oocyte collection.
d) Ensure that no more than two embryos or oocytes are transferred to a recipient woman, of any age, in any one treatment cycle, where the oocytes are donated from a woman aged less than 40 years at the time of oocyte collection.

e) Ensure single embryo transfer is mandatory for a gestational carrier in surrogacy arrangements.

f) In the formation of embryo transfer number policies, there be documented consideration of available resources to manage the risks of multiple pregnancy and premature delivery.

g) Ensure that patients receive information on the economic, medical, social and psychological hazards associated with multiple pregnancy.

**CC 11. Data monitoring**

*The ART Unit must undertake regular reviews of treatment outcomes.*

The ART Unit must provide evidence of implementation and review of policies/procedures to:

- a) identify, collect, analyse and review data to monitor treatments and treatment outcomes at least annually.
- b) benchmark the Unit’s clinical outcomes against national and international standards
- c) proactively follow up outcomes of treatment, including live births where possible

**CC 12. Data reporting**

*The ART Unit must comply with national and institutional requirements for the provision of treatment data, and must inform patients of the uses to which their medical information may be put.*

The ART Unit must provide evidence of:

- a) Compliance with national and institutional reporting requirements.
- b) Implementation and review of policies/procedures for informing patients on the use of identifying and de-identified medical information that will be provided to statutory, regulatory and legislative authorities, certifying bodies, and any other relevant parties.
PART 2  GOOD PRACTICE CRITERIA

AUDIT OF ALL GOOD PRACTICE CRITERIA AT THE INITIAL CERTIFICATION AUDIT AND SUBSEQUENTLY OVER A THREE YEAR PERIOD OF ANNUAL INSPECTIONS, IN ACCORDANCE WITH THE RTAC CERTIFICATION SCHEME

(WHERE, IN ACCORDANCE WITH NATIONAL LEGISLATION/REGULATIONS, ASSESSMENTS ARE LESS FREQUENT THAN ANNUALLY, ALL GOOD PRACTICE CRITERIA SHOULD BE AUDITED AT EACH ASSESSMENT)
GPC 1. Quality management system (QMS)

The Unit must have a management system allowing planned, implemented, coordinated, and appropriate service delivery which meets the needs of all stakeholders.

Provide evidence of implementation and review of the following QMS elements.

a) A Quality Management policy that:
   i) Demonstrates management commitment,
   ii) Outlines the scope of services provided, including identification of key, outsourced personnel and services,
   iii) Shows organisational objectives,

b) Management review processes that review the scope, organisational objectives and relevance of the quality management system,

c) Integration of all personnel and services:
   i) Records confirming service integration.

d) Records management:
   i) Compliance with statutory and regulatory authorities,
   ii) Document control system showing evidence of implementation, approval and review of internal and external documents,
   iii) Systems of internal communication including copies of meeting minutes, emails and memos.

e) Personnel training and competency:
   i) Staff and/or contractors with appropriate and documented expertise to cover all aspects of the organisation’s services,
   ii) Management commitment to adequate staffing, training and ongoing education,
   iii) Identification of training and education needs,
   iv) Records of induction, training and ongoing education,
   v) Records of relevant professional registration,
   vi) Outline of responsibility and authority,
   vii) Policies and procedures for training and ongoing competence assessment to cover aspects assessed, the frequency of assessment and the required achievement levels,
viii) Competency criteria including skill, education, training and experience,

ix) Records of each individual's competency for all services both internal and external.

f) Buildings and facilities:

i) Assessment of requirements to meet organisational goals,

ii) Adequate facilities and equipment to meet objectives. Where any part of the ART process occurs in a surgical facility remote from the clinic and/or laboratory, audit of processes (including identification and traceability) and equipment in these facilities and during transport of reproductive tissues between facilities must form part of the audit,

iii) Records of QC validation, maintenance and service of equipment including the frequency of testing.

iv) Security, particularly to protect confidentiality of records and integrity of gametes and embryos,

v) All facilities where surgical procedures are conducted within an ART Unit need to provide evidence of policies and procedures to manage patient safety and assess risk.

g) Risk management:

i) Assessment of risks,

ii) Review of risk,

iii) Incident reporting and response,

iv) Corrective and preventative action,

v) Workplace health and safety

h) Key supplier management:

i) Including records of service agreements with key contractors and key contracted service providers.

i) Auditing:

i) Audit schedule,

ii) Internal audits in compliance with the audit schedule,

iii) Annual RTAC surveillance audits to be scheduled more than 30 days prior to expiry date of their RTAC certification.
GPC 2. Stakeholder feedback

The Unit must undertake regular stakeholder feedback, and acknowledge and investigate complaints.

The ART Unit must provide evidence of implementation and review of policies/procedures to collect, analyse, review and take relevant action on stakeholder feedback including patient stakeholders. It must also acknowledge and investigate complaints, and provide evidence of implementation and review of policies and procedures which include:

a) Information on how patients make a complaint and how they receive feedback,

b) Acknowledgement and investigation of complaints,

c) Systematic recording, review and corrective action of complaints.

GPC 3. Medical management

The Unit must ensure that it meets the reproductive health needs of the patients and partners under its care.

Provide evidence of implementation and review of policies/procedures so that:

a) Women undergo clinical evaluation for co-existing reproductive health or gynaecological problems, or those arising as a result of ART treatment

b) Men undergo clinical evaluation for co-existing reproductive health and related problems, or those arising as a result of ART treatment

c) There are pathways of referral for endocrine and andrological expertise

d) Preconceptual advice should be provided to couples, including the consequences of abnormal weight, smoking, adverse environmental exposure and other relevant factors. This should be incorporated into referral pathways to ensure optimal health before fertility treatment.
GPC 4. Information

GPC 4.1. Patient information

*The ART Unit must provide patients with information that is accurate, timely and in formats appropriate to the patient.*

Provide evidence of implementation and review of policies/procedures that ensure:

a) Patients receive written and verbal information covering diagnosis, investigation and fertility treatment options.

b) The availability of a process to ensure information provision in comprehensible formats and language appropriate to the target audience.

c) Information is easy to understand and not misleading in any way.

Patient information must include but not be limited to:

i) Processes, costs, risks and outcomes.

ii) Drugs and side effects.

iii) Availability of individual counselling and support groups.

iv) Patient rights and responsibilities consistent with national policy.

v) Availability of translation and interpreter services.

vi) Preconception advice including the consequences of abnormal weight, smoking, adverse environmental exposure and other relevant factors.

vii) A statement that donor and surrogacy arrangements are likely to require multiple counselling sessions.

GPC 4.2. Public information

*Information presented in the public domain must be accurate and balanced, and easily understood by the lay public.*

Public information must be consistent with local jurisdictional requirements and in the absence of local requirements the following will apply:

a) Success rates where given must:

i) be divided by age,

ii) specify live birth rates for fresh and frozen embryo transfers separately,
iii) be accompanied with the following clarifying information: the time period during which the advertised data was collected and unambiguous details of the population group from which they are derived (e.g. whether they relate to IVF, ICSI, PGS/PGD or FET, and age group),

iv) be accompanied by a qualifying statement of broad factors that affect success rates e.g. age, weight, and cause of infertility, and that individual results will vary with individual circumstances,

v) be accompanied by a statement that not every treatment cycle will result in an egg collection, an embryo transfer or embryo cryopreservation,

vi) ensure that any clarification, qualifying statement or reference be clear and prominent and not hidden in a disclaimer.

b) ART Units must ensure their websites comply with the above requirements, and document this through regular internal audits.

GPC 5. Medication management

The Unit must ensure the safe management of drug storage, supply and administration.

Provide evidence of implementation and review of policies/procedures which include:

a) Authorising orders for drugs that are to be supplied or administered to patients.

b) Recording in the patient’s individual file / record, all drugs that are supplied or administered to patients by the ART Unit. Batch numbers of drugs used, where available, should be recorded in a drug register. Where drugs are dispensed through a pharmacy or equivalent this is not a requirement.

c) Maintenance of accurate records and audit of the drug management system.

d) The safe procurement, storage and disposal of drugs.

e) Management of returned drugs to ensure drugs are not reissued.

f) Management of drugs to ensure that they are always used within expiry date.
GPC 6. Emergency care

The Unit must ensure access to emergency care.

Provide evidence of implementation and review of policies/procedures:

a) On emergency physical and psychological care.

b) That must ensure patients receive information on how to access emergency care including out of normal hours.

GPC 7. Ovarian hyperstimulation syndrome

The Unit must minimise the incidence of Ovarian Hyperstimulation Syndrome (OHSS).

Provide evidence of implementation and review of policies/procedures:

a) For the identification and management of patients at risk of, or experiencing, OHSS.

b) That measure and attempt to minimise the incidence of OHSS.

c) That must ensure patients receive information on the risks, symptoms and management of OHSS.

d) That must ensure patients receive information on how to access help, advice or care out of normal hours or in the event of medical emergency.
PART 3 ESTABLISHMENT AND CLOSURE OF AN ART UNIT
Initial Certification of an ART Unit

The Unit must ensure compliance with the RTAC Certification Scheme and the RTAC International Code of Practice.

The primary audit conducted by a Certifying Body on a clinic applying for certification, and prior to it’s receiving a license from RTAC should include:

a) Compliance with all aspects of the RTAC International Code of Practice with the exception of treatment records and outcome data analysis

b) A fully documented clinic policy manual

c) A fully documented policy and procedure manual for each area of the clinic e.g. including but not limited to clinical, nursing and medication management, laboratory, counselling and administration

d) A fully documented Quality Management System

e) A fully documented Risk Assessment and Management policy and records of identified risks and their management strategies

f) Installation and validation of ALL proposed equipment for use in the clinic, in particular laboratory, drug storage, clinical and sterilisation equipment.

g) Records of an internal audit to verify compliance with these requirements performed by clinic personnel prior to the Certifying Body audit.

A Unit being certified for the first time must complete an internal audit of its Quality Management System and patient, gamete and embryo identification processes prior to the certification inspection by the Certifying Body.

RTAC has the right to require a further inspection after procedures have been performed.

Closure or Discontinuation of Certification of an ART Unit

The ART Unit should ensure the ongoing safe storage and accessibility of gametes, embryos, tissues and medical records. It must inform the relevant statutory and regulatory authorities, RTAC and the Certifying bodies, and all stakeholders of the processes carried out to ensure this safe storage and accessibility. This is for information only and not part of the auditable standard.
ATTACHMENT 1

Donor & Surrogacy Requirements

The ART Unit must provide evidence of implementation and review of policies/procedures to ensure:

a) compliance with national legislation and/or guidelines on the donation of biological tissues, the donation of gametes and embryos, the provision of services for surrogacy agreements;

b) commercial surrogacy is not undertaken;

c) support of the donor-offspring’s right to know their genetic origin and to have in place policies and procedures for donor-offspring linking;

d) where there is no relevant donation or surrogacy legislative requirements, clinics must develop policies and procedures to ensure agreements are in place to outline the medical and legal consequences of the arrangement including any financial arrangements and the rights of the donor/surrogate with regards to withdrawal from the arrangement;

e) that there be documented clinic-determined criteria for eligibility for donors and surrogates;

f) comprehensive identifying and non-identifying information is collected about each donor and/or surrogate including last known address and relevant medical history of immediate family;

g) records about donors, recipients and surrogates are retained indefinitely;

h) that donors, recipients and/or the surrogate have attended a counselling process that includes (but is not limited to);

i. the advantages of telling any resulting child of its genetic origin

ii. local legislation defining the legal status of any child born as a result of the procedure

iii. any genetic or infectious disease screening to be carried out and the implications of having a positive result.

iv. Implications of donating or receiving donated gametes or embryos, or participating in surrogacy

i) the partners of the donor, the recipient and/or the surrogate must be included in the counselling and consenting process;

j) That policies and procedures are in place, which have been developed in conjunction with the senior counsellor, in relation to these treatment arrangements. For known donation, an additional joint session involving all parties must be undertaken prior to the signing of consents;

k) that counselling has been undertaken by a counsellor who has tertiary qualifications in a clinical profession, recognised in the country of the unit, such as psychiatry, psychology, social work or counselling;

l) valid and informed consent, including acknowledgment of risks to the donor, has been obtained without coercion for the collection and donation and/or the surrogacy and the final point at which consent can be withdrawn without financial penalty defined;
m) the risk of transmission of infectious agents and genetic conditions between donors of gametes and/or embryos is minimised. It is a requirement that donors inform the clinic of any known genetic condition that they or close family members are diagnosed with prior or subsequent to donating;

n) there is a limitation on the number of families from one donor, to comply with national regulations/guidelines and to minimise the potential risk of future consanguinity. In the absence of regulations or guidelines there must be documented clinic-determined family limits for donors and evidence of monitoring these family limits;

o) donors are required to declare if they have donated at other clinics to ensure that the family limit is maintained.
ATTACHMENT 2

Definitions

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>A Serious Adverse Event is any event associated with ART treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- which causes or potentially causes harm, loss or damage to</td>
</tr>
<tr>
<td></td>
<td>patients or their reproductive tissues</td>
</tr>
<tr>
<td></td>
<td>- which results in hospitalisation following, and as a result of,</td>
</tr>
<tr>
<td></td>
<td>the treatment.</td>
</tr>
<tr>
<td></td>
<td>Serious adverse events must be investigated, fully documented,</td>
</tr>
<tr>
<td></td>
<td>and corrective actions put in place for review by the Certifying</td>
</tr>
<tr>
<td></td>
<td>Body at the next scheduled inspection.</td>
</tr>
<tr>
<td></td>
<td>A Serious Notifiable Adverse Event is an abnormal unintended</td>
</tr>
<tr>
<td></td>
<td>outcome associated with ART treatment which:</td>
</tr>
<tr>
<td></td>
<td>- might result in the transmission of a communicable disease</td>
</tr>
<tr>
<td></td>
<td>- might result in death or a life-threatening, disabling, or</td>
</tr>
<tr>
<td></td>
<td>incapacitating condition</td>
</tr>
<tr>
<td></td>
<td>- arises from a gamete or embryo identification error or mix-up.</td>
</tr>
<tr>
<td></td>
<td>Serious Reportable Adverse Events must be reported within 6</td>
</tr>
<tr>
<td></td>
<td>weeks to relevant local authorities, RTAC and the Certifying</td>
</tr>
<tr>
<td></td>
<td>Body, along with a summary of investigation of the event and any</td>
</tr>
<tr>
<td></td>
<td>actions taken.</td>
</tr>
</tbody>
</table>

<p>| ANZARD          | Australian and New Zealand Assisted Reproduction Database       |
| Appoint         | When the Unit employs, hires, contracts with, chooses, or      |
|                | arranges for a particular individual to provide a certain role. |
| ART             | Assisted Reproductive Technology                                |
| Artificial Insemination | The controlled and planned ART process by which sperm is      |
| ART Unit        | A facility that uses, assesses and/or prepares human gametes    |
|                 | and/or embryos for therapeutic service, possibly across a      |
| Audit           | A systematic, independent examination and review to determine   |
| Authority       | The proper powers to carry out an action whether granted       |
|                 | directly or delegated.                                         |
| <strong>Certification</strong> | A third party assessment of the quality system of the service provider with respect to published quality system standards and any supplementary documentation required under the system (for example ISO 19011:2011). |
| <strong>Competent</strong> | Having the required ability, knowledge or authority. |
| <strong>Deed of Agreement</strong> | A current signed agreement with the FSA to comply with the RTAC Code of Practice is required prior to each certification audit. |
| <strong>Facility</strong> | The physical location, site or building within or from which the service is provided. |
| <strong>FSA</strong> | Fertility Society of Australia |
| <strong>Governance</strong> | Taking responsibility for the overall direction of the Unit, including determination of the purpose and goals of the service. |
| <strong>Integration</strong> | When the Unit involves, assimilates, incorporates or amalgamates individuals into its day to day activities. |
| <strong>Management</strong> | Implementing the policy determined by the governing body and coordinating the day to day service activity which achieve the purpose and goals of the Unit. |
| <strong>Must</strong> | Where it is mandatory in every circumstance to perform the required task with no exception. |
| <strong>Ovulation Induction</strong> | The controlled and planned ART process whereby hormonal stimulation is employed to induce the process of ovulation. |
| <strong>Patient</strong> | A user or participant in the service including donors. |
| <strong>Policy</strong> | Overall intentions and directions of a Unit. |
| <strong>Procedure</strong> | A specific way to carry out an activity. |
| <strong>Process</strong> | A set of interrelated or interactive activities which are planned and carried out under controlled conditions. |
| <strong>Quality Policy</strong> | Overall intentions and direction of a Unit related to quality as formally expressed by top management. |
| <strong>Records</strong> | A description of the healthcare provided for an identifiable patient/donor. May be a single file, multiple files, hard copy or electronic and be held by a Unit, service provider or the patient/donor themselves. This also includes documented information determined by the organisation as being necessary for the effectiveness of the business and management. |</p>
<table>
<thead>
<tr>
<th><strong>Review</strong></th>
<th>A formal process of updating, amending, or replanning that is based on evaluation of outcomes.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk</strong></td>
<td>The chance of something happening which will have an adverse impact on objectives.</td>
</tr>
<tr>
<td><strong>Risk management</strong></td>
<td>The culture, processes and structures that are directed towards realising potential opportunities whilst managing adverse effects.</td>
</tr>
<tr>
<td><strong>Sero-discordant</strong></td>
<td>Where one partner is infected with a sexually transmitted disease and the other is not.</td>
</tr>
<tr>
<td><strong>Service provider</strong></td>
<td>An individual who is responsible for providing the service either independently or on behalf of a Unit. This includes all staff and management who are employed, self-employed, visiting, honorary, sessional, contracted or volunteer.</td>
</tr>
<tr>
<td><strong>Stakeholders</strong></td>
<td>Person or group having an interest in the performance or success of a Unit, including but not limited to staff, patients, owners, major suppliers, funding organisations and community</td>
</tr>
<tr>
<td><strong>Supervision</strong></td>
<td>An activity that aims to enable the supervisee to achieve, sustain and develop a high quality practice through the means of focused support and development.</td>
</tr>
<tr>
<td><strong>Therapeutic Service</strong></td>
<td>Service aimed at treating patients, such as IVF, IUI. It does not include diagnostic procedures e.g. semen analysis.</td>
</tr>
<tr>
<td><strong>Valid Consent</strong></td>
<td>For consent to be valid:</td>
</tr>
<tr>
<td></td>
<td>- the person giving consent must be considered to have the capacity to provide consent,</td>
</tr>
<tr>
<td></td>
<td>- the decision to consent to the treatment or procedure must be made without undue pressure,</td>
</tr>
<tr>
<td></td>
<td>- the consent must be specific, and is effective only in relation to the treatment or procedure for which information has been given.</td>
</tr>
</tbody>
</table>
ATTACHMENT 3

Please supply the following information about any serious adverse event to the RTAC secretariat and your Certifying Body within 6 weeks as required in CC 9 of the RTAC Code of Practice.

<table>
<thead>
<tr>
<th>ART Unit name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of event as per Code of Practice</td>
<td></td>
</tr>
<tr>
<td>Clinical presentation and intervention (with dates)</td>
<td></td>
</tr>
<tr>
<td>Patient outcome</td>
<td></td>
</tr>
<tr>
<td>Corrective action taken</td>
<td></td>
</tr>
<tr>
<td>Date of conclusion of event</td>
<td></td>
</tr>
<tr>
<td>Member of Key Personnel reviewing the case, and date of review</td>
<td></td>
</tr>
</tbody>
</table>

Return to:

FSA Secretariat, Waldron Smith Management, 119 Buckhurst Street, South Melbourne VIC 3205 Australia (e-mail: kimo@wsm.com.au)